Cizzle Bio, Inc. proudly announces the appointment of Joseph Kelley, retired Eli Lilly Executive, to its Board of Directors. With over 25 years of experience in business, public policy, and regulatory affairs, Mr. Kelley brings exceptional leadership to support Cizzle Bio’s mission to revolutionize early cancer detection.

We are excited to announce that Dr. William S. Dalton, renowned oncology expert and former CEO of Moffitt Cancer Center, has joined Cizzle Bio, Inc. as the Head of Clinical Trials. Dr. Dalton’s extensive experience in precision medicine and cancer research will play a vital role in advancing our innovative diagnostic solutions for early cancer detection.

Cizzle Bio, Inc. has entered into a strategic partnership with BBI Solutions to manufacture commercial monoclonal antibodies for early-stage lung cancer detection. This collaboration marks a significant milestone in Cizzle Bio's mission to bring the CIZ1B biomarker test to market. The first batch will support up to 5000 tests and facilitate critical clinical evaluations with a major US cancer center.